Novartis and Microsoft will use artificial intelligence (AI) technology to discover, develop and commercialise medicines. Credit: Novartis AG.

Novartis has allied with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and commercialisation of medicines.

Under the multi-year collaboration, Novartis established an AI innovation lab, where the pharmaceutical company’s datasets will be combined with Microsoft’s AI solutions to generate AI models and applications that can aid researchers.

Related Company Profiles

View all

The lab will also use AI for generative chemistry, as well as image segmentation and analysis to enable personalised treatments and at-scale optimisation of cell and gene therapies.

Furthermore, the partners will develop and apply AI platforms and processes to support future programmes in the two fields.

Novartis CEO Vas Narasimhan said: “As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend patients’ lives.

“Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The companies will work together at Novartis Campus in Switzerland, Novartis Global Service Center in Dublin, Ireland and Microsoft Research Lab in the UK.

Initially, the research will focus on personalised therapies for macular degeneration, cell and gene therapies and drug design.

Microsoft CEO Satya Nadella said: “Our strategic alliance will combine Novartis’ life sciences expertise with the power of Azure and Microsoft AI.

“Together, we aim to address some of the biggest challenges facing the life sciences industry today and bring AI capabilities to every Novartis employee so they can unlock new insights as they work to discover new medicines and reduce patient costs.”

The overall investment for the partnership will involve project funding, subject-matter experts, technology and tools, noted Novartis.